AR020199A1 - AGONIST COMPOUNDS AND MUSCARINIC ANTAGONISTS UNDERSTANDING A AZACICLIC RING SYSTEM, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND USING THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. - Google Patents
AGONIST COMPOUNDS AND MUSCARINIC ANTAGONISTS UNDERSTANDING A AZACICLIC RING SYSTEM, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND USING THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.Info
- Publication number
- AR020199A1 AR020199A1 ARP990104100A ARP990104100A AR020199A1 AR 020199 A1 AR020199 A1 AR 020199A1 AR P990104100 A ARP990104100 A AR P990104100A AR P990104100 A ARP990104100 A AR P990104100A AR 020199 A1 AR020199 A1 AR 020199A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- alkyl
- halogen
- alkoxy
- branched
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000003149 muscarinic antagonist Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- -1 -OH Inorganic materials 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 3
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 abstract 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 2
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101100533890 Hypocrea jecorina (strain QM6a) sor3 gene Proteins 0.000 abstract 1
- 101100533874 Hypocrea jecorina (strain QM6a) sor5 gene Proteins 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos agonistas y antagonistas muscarínicos que comprenden un sistema de anillo azacíclico que tiene la formula 1 incluyendo sus isomeros geométricos,enantiomeros, diastereomeros, racematos, sales de adicion de ácido, sales de los mismos con unácido faramcéuticamente aceptable y pro-drogas de los mismos, endonde Q es de formula 2 a 10 , X es CH2, NH O o S; V, W, Y y Z son independientemente CH o N; n y m son independientemente 0, 1, 2, 3 o 4; R1 y R2 están encualquier posicion en elanillo azacíclico, incluyendo el punto de union del heterocíclo Q e independientemente, son hidrogeno, -OH, halogeno, -NH2, carboxi,alquil C1-10, recto o ramificado, alquenil C1-10 o alquinil C1-10, alcoxi C1-10 recto o ramificado o alquil C1-10recto o ra mificado, sustituido con -OH, -CN,-CHO, -OH, -OR3, - SR3, -NH2, NHR3, NR3R4, -NO2, SOR3, SO2R3, -COR3, CO2R3, -CONH2, CONHR3, CONR3R4 o -CH=NOR3; o R1 y R2 son independientemente fenil, fenoxi,benzoil, bencil o benciloxicarbonil, cada unode los cual es está no-sustituido o sustituido con halogeno, -CN, alquil C1-10, alcoxi C1-10 o alquiltio C1-10,R es hidrogeno, halogeno, -CN, -CHO, -OH, OR3, -SR3, -NH2, NHR3, -NR3R4, -NO2, -SOR3, -SO2R3, -COR3, -CO2R3, CONH2, -CONHR3, -CONR3R4 oCH=NOR3; o R es fenil,fenoxi, benzoíl, bencil o benciloxicarbonil, cada uno de los cuales está no sustituido o sustituido con halogeno, -CN, alquil C1-15, alcoxi C1-10 o alquiltioC1-10; o R es un anillo heterocíclico de 5 o 6 miembros saturado,parcialmente saturad o o aromático que contiene uno a tres heteroátomos; y R3 y R4 sonindependientemente alquil C1-15, recto, ramificado o cíclico, alquenil C2-15, alquinil C2-15 o combinaciones de los mismos, o R3 y R4 son independientementegruposfenil, fenoxi, benzoi l, bencil, o benciloxicarbonil, cada uno de los cuales están no sustituidos o sustituidos con H, halogeno, -CN, alquil C1-15,alcoxi C1-10, alquiltio C1-10 o aril; o R3 y R4 son independientemetne anillos heterocíclicos de 5 o6 miembros, saturados, parcialmente saturados o aromáticos, que contienen uno a tres heteroátomos, composicion farmacéutica que los comprende, y el uso de los mismos para la manufactura de un medicamento.Agonist and muscarinic antagonist compounds comprising an azacyclic ring system having formula 1 including its geometric isomers, enantiomers, diastereomers, racemates, acid addition salts, salts thereof with a pharmaceutically acceptable acid and pro-drugs thereof, where Q is of formula 2 to 10, X is CH2, NH O or S; V, W, Y and Z are independently CH or N; n and m are independently 0, 1, 2, 3 or 4; R1 and R2 are in any position in the azacyclic ring, including the point of attachment of heterocyclic Q and independently, they are hydrogen, -OH, halogen, -NH2, carboxy, C1-10 alkyl, straight or branched, C1-10 alkenyl or C1 alkynyl -10, straight or branched C1-10 alkoxy or straight or branched C1-10 alkyl, substituted with -OH, -CN, -CHO, -OH, -OR3, - SR3, -NH2, NHR3, NR3R4, -NO2, SOR3 , SO2R3, -COR3, CO2R3, -CONH2, CONHR3, CONR3R4 or -CH = NOR3; or R1 and R2 are independently phenyl, phenoxy, benzoyl, benzyl or benzyloxycarbonyl, each of which is unsubstituted or substituted by halogen, -CN, C1-10 alkyl, C1-10 alkoxy or C1-10 alkylthio, R is hydrogen, halogen, -CN, -CHO, -OH, OR3, -SR3, -NH2, NHR3, -NR3R4, -NO2, -SOR3, -SO2R3, -COR3, -CO2R3, CONH2, -CONHR3, -CONR3R4 oCH = NOR3; or R is phenyl, phenoxy, benzoyl, benzyl or benzyloxycarbonyl, each of which is unsubstituted or substituted with halogen, -CN, C1-15 alkyl, C1-10 alkoxy or C1-10 alkylthio; or R is a saturated, partially saturated or aromatic 5 or 6 membered heterocyclic ring containing one to three heteroatoms; and R3 and R4 are independently C1-15 alkyl, straight, branched or cyclic, C2-15 alkenyl, C2-15 alkynyl or combinations thereof, or R3 and R4 are independently groups phenyl, phenoxy, benzoyl, benzyl, or benzyloxycarbonyl, each of which are unsubstituted or substituted with H, halogen, -CN, C1-15 alkyl, C1-10 alkoxy, C1-10 alkylthio or aryl; or R3 and R4 are independently 5 or 6 membered heterocyclic rings, saturated, partially saturated or aromatic, containing one to three heteroatoms, pharmaceutical composition comprising them, and the use thereof for the manufacture of a medicament.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9697798P | 1998-08-18 | 1998-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020199A1 true AR020199A1 (en) | 2002-05-02 |
Family
ID=22260061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104100A AR020199A1 (en) | 1998-08-18 | 1999-08-17 | AGONIST COMPOUNDS AND MUSCARINIC ANTAGONISTS UNDERSTANDING A AZACICLIC RING SYSTEM, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND USING THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US6093724A (en) |
| EP (1) | EP1112272B1 (en) |
| JP (1) | JP2002523416A (en) |
| KR (1) | KR20010072784A (en) |
| CN (1) | CN1312812A (en) |
| AR (1) | AR020199A1 (en) |
| AT (1) | ATE227724T1 (en) |
| AU (1) | AU750566B2 (en) |
| BG (1) | BG105256A (en) |
| BR (1) | BR9913072A (en) |
| CA (1) | CA2340946A1 (en) |
| CO (1) | CO5130018A1 (en) |
| DE (1) | DE69903961T2 (en) |
| EE (1) | EE200100096A (en) |
| ES (1) | ES2191455T3 (en) |
| HK (1) | HK1038918A1 (en) |
| HU (1) | HUP0103203A3 (en) |
| ID (1) | ID27544A (en) |
| IL (1) | IL141050A0 (en) |
| IS (1) | IS5827A (en) |
| NO (1) | NO20010804L (en) |
| NZ (1) | NZ509762A (en) |
| PE (1) | PE20000988A1 (en) |
| PL (1) | PL346247A1 (en) |
| RU (1) | RU2219179C2 (en) |
| SK (1) | SK1892001A3 (en) |
| TR (1) | TR200100462T2 (en) |
| WO (1) | WO2000011001A1 (en) |
| YU (1) | YU13301A (en) |
| ZA (1) | ZA200100978B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1326867A2 (en) * | 2000-10-19 | 2003-07-16 | Pfizer Products Inc. | Bridged piperazine derivatives |
| GB0117950D0 (en) * | 2001-02-16 | 2001-09-19 | Aventis Pharma Inc | Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands |
| WO2002094827A1 (en) * | 2001-05-23 | 2002-11-28 | Neurosearch A/S | Fused tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US20030064979A1 (en) * | 2001-06-29 | 2003-04-03 | Hansen Thomas Kruse | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 |
| US6828328B1 (en) * | 2002-03-01 | 2004-12-07 | Ucb S.A. | Analgesic combination of muscarinic agonists |
| US7897766B2 (en) | 2005-09-23 | 2011-03-01 | Abbott Laboratories | Amino-aza-adamantane derivatives and methods of use |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| US8076350B2 (en) * | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
| CN101641356B (en) | 2007-03-23 | 2012-09-05 | 雅培制药有限公司 | Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof |
| CN102690265A (en) * | 2007-03-23 | 2012-09-26 | 雅培制药有限公司 | 4-substituted azaadamantane derivatives and methods of use thereof |
| AU2010262643B2 (en) * | 2009-06-19 | 2015-02-19 | Abbvie Inc. | Diazahomoadamantane derivatives and methods of use thereof |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| EP3646870A1 (en) | 2009-07-22 | 2020-05-06 | Puretech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (en) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME |
| AR081626A1 (en) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS |
| CN103180321A (en) * | 2010-09-23 | 2013-06-26 | Abbvie公司 | Monohydrate of azaadamantane derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| EP3732163A4 (en) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4 |
| EP3856182B1 (en) | 2018-09-28 | 2025-12-24 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4739074A (en) * | 1986-01-22 | 1988-04-19 | Pennwalt Corporation | Adamantane spiro-pyrrolidine derivatives |
| IL88156A (en) * | 1987-11-13 | 1997-02-18 | Novo Nordisk As | Azacyclic compounds their preparation and pharmaceutical compositions containing them |
| US5527813A (en) * | 1990-08-21 | 1996-06-18 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
| WO1992011261A1 (en) * | 1990-12-21 | 1992-07-09 | Merck Sharp & Dohme Limited | 4-azatricyclo[2.2.1.02,6]heptanes and pharmaceutical compositions |
| US5955470A (en) * | 1991-06-11 | 1999-09-21 | Merrell Pharmaceuticals, Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
| US5641791A (en) * | 1991-08-13 | 1997-06-24 | Novo Nordisk A.S | Heterocyclic compounds and their preparation and use |
| NZ321970A (en) * | 1995-11-02 | 2000-02-28 | Neurosearch As | Fused tropane-derivatives as neurotransmitter reuptake inhibitors |
| US5914338A (en) * | 1996-04-02 | 1999-06-22 | Novo Nordisk | Heterocyclic compounds and their preparation and use |
| US5986100A (en) * | 1998-04-02 | 1999-11-16 | Crooks; Peter Anthony | Pharmaceutical compositions and methods for use |
| US5952339A (en) * | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| US6057446A (en) * | 1998-04-02 | 2000-05-02 | Crooks; Peter Anthony | Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds |
-
1999
- 1999-08-16 EP EP99945064A patent/EP1112272B1/en not_active Expired - Lifetime
- 1999-08-16 US US09/375,149 patent/US6093724A/en not_active Expired - Fee Related
- 1999-08-16 HU HU0103203A patent/HUP0103203A3/en unknown
- 1999-08-16 YU YU13301A patent/YU13301A/en unknown
- 1999-08-16 JP JP2000566274A patent/JP2002523416A/en active Pending
- 1999-08-16 CA CA002340946A patent/CA2340946A1/en not_active Abandoned
- 1999-08-16 EE EEP200100096A patent/EE200100096A/en unknown
- 1999-08-16 HK HK02100409.3A patent/HK1038918A1/en unknown
- 1999-08-16 CN CN99809775A patent/CN1312812A/en active Pending
- 1999-08-16 DE DE69903961T patent/DE69903961T2/en not_active Expired - Fee Related
- 1999-08-16 AT AT99945064T patent/ATE227724T1/en not_active IP Right Cessation
- 1999-08-16 AU AU57758/99A patent/AU750566B2/en not_active Ceased
- 1999-08-16 KR KR1020017002128A patent/KR20010072784A/en not_active Withdrawn
- 1999-08-16 PL PL99346247A patent/PL346247A1/en not_active Application Discontinuation
- 1999-08-16 ES ES99945064T patent/ES2191455T3/en not_active Expired - Lifetime
- 1999-08-16 RU RU2001107139/04A patent/RU2219179C2/en not_active IP Right Cessation
- 1999-08-16 ID IDW20010377A patent/ID27544A/en unknown
- 1999-08-16 IL IL14105099A patent/IL141050A0/en unknown
- 1999-08-16 TR TR2001/00462T patent/TR200100462T2/en unknown
- 1999-08-16 NZ NZ509762A patent/NZ509762A/en unknown
- 1999-08-16 SK SK189-2001A patent/SK1892001A3/en unknown
- 1999-08-16 BR BR9913072-6A patent/BR9913072A/en not_active IP Right Cessation
- 1999-08-16 WO PCT/US1999/018570 patent/WO2000011001A1/en not_active Ceased
- 1999-08-17 AR ARP990104100A patent/AR020199A1/en unknown
- 1999-08-18 CO CO99052330A patent/CO5130018A1/en unknown
- 1999-08-18 PE PE1999000838A patent/PE20000988A1/en not_active Application Discontinuation
-
2000
- 2000-05-09 US US09/567,785 patent/US6251916B1/en not_active Expired - Fee Related
- 2000-10-17 US US09/690,494 patent/US6323194B1/en not_active Expired - Fee Related
-
2001
- 2001-01-26 IS IS5827A patent/IS5827A/en unknown
- 2001-02-05 ZA ZA200100978A patent/ZA200100978B/en unknown
- 2001-02-14 BG BG105256A patent/BG105256A/en unknown
- 2001-02-16 NO NO20010804A patent/NO20010804L/en not_active Application Discontinuation
- 2001-10-05 US US09/972,415 patent/US6423842B1/en not_active Expired - Fee Related
-
2002
- 2002-03-27 US US10/108,046 patent/US6555550B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR020199A1 (en) | AGONIST COMPOUNDS AND MUSCARINIC ANTAGONISTS UNDERSTANDING A AZACICLIC RING SYSTEM, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND USING THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
| ES2100187T3 (en) | DERIVATIVES OF CARBOESTIRILOS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| FI841181A0 (en) | NYA N-PHENYL-N'- CYCLOALKYLALKANOYLPIPERAZINER OCH FOERFARANDE FOER DERAS FRAMSTAELLNING. | |
| ES2721268T3 (en) | Pyrazolo [1,5-a] pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | |
| ATE110075T1 (en) | 1,2-BENZISOXAZOLE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| AR025386A1 (en) | MODULATORS OF ACTIVATED RECEIVERS OF THE PEROXISOM PROLIFER | |
| ES2036220T3 (en) | NEW OXAZOLIDINES. | |
| ES2294313T3 (en) | PIRIDINE DERIVATIVES AS MODULATORS OF THE CB2 RECEIVER. | |
| ES2093099T3 (en) | PREPARATION OF SUBSTITUTED PIPERIDINES. | |
| PE20000127A1 (en) | BENZENOSULFONAMIDE DERIVATIVE | |
| DE69004112D1 (en) | Arrangement for the high voltage supply of an X-ray tube. | |
| NO306510B1 (en) | Androsterones, their use, and pharmaceutical formulation | |
| ES2058191T3 (en) | 2-PHENYL-4-CHINOLINCARBOXYLIC ACIDS SUBSTITUTED. | |
| CO5040177A1 (en) | COMPOSITIONS AND SALTS OF N-ALQUILAMONIO ACETONITRILO AND METHOD TO MANUFACTURE THEM | |
| ATE29032T1 (en) | SPIRO(2,2,6,6-TETRAMETHYL-PIPERIDINE-4,2'-(1',3'DIOXO(OL)ANE> DERIVATIVES AND STABILIZERS FOR SYNTHETIC POLYMERS. | |
| AR028968A1 (en) | HETEROCICLIC DERIVATIVES OF AMINOALQUILPIRIDINA AS PSYCHOPHARMS | |
| MX9306257A (en) | PHOTOCHROME COMPOUNDS, THEIR PREPARATION AND USE. | |
| ES2038656T3 (en) | DERIVATIVES OF THYOMETHYLPENICILLIN SUBSTITUTED IN BETA AND ITS PREPARATION AND USE. | |
| DE3856387D1 (en) | 1,2,3,4,10,14b-HEXAHYDRODIBENZO-c, f] PYRAZINO-1,2-a] AZEPINO DERIVATIVES | |
| ES509636A0 (en) | "PROCEDURE TO PREPARE NEW AROILIMIDAZOLE-2-ONAS COMPOUNDS". | |
| ES2062495T3 (en) | NEW BRONCHOSPASMOLITICAL COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION. | |
| FI861934A0 (en) | NYA ISOXAZOLDERIVAT, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DESSA INNEHAOLLANDE FARMACEUTISKA PREPARAT. | |
| ATE10937T1 (en) | CYCLOPROPYLMETHYL PIPERAZINE, THEIR PRODUCTION PROCESSES AND THEIR USE IN THERAPEUTICS. | |
| IT8068199A0 (en) | EQUIPMENT FOR COATING HOLLOW PARTS BY MEANS OF ELECTROSTATIC DUST PROJECTION | |
| AR029989A1 (en) | STEROID COMPOUNDS 16 ALFA-SUBSTITUTES FOR USE IN TREATMENTS RELATED TO STROGEN RECEIVERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |